Insights

Brussels – March 24, 2026: Chambers and Partners has ranked five Crowell & Moring practice groups and 11 individual lawyers in the Chambers Europe 2026 guide.

Boston – February 17, 2026: Crowell & Moring represented GelMEDIX, Inc., a biotechnology company focused on regenerative therapies for vision restoration, in the closing of its $13 million seed financing. The round was led by Safar Partners, with participation from HTL Biotechnology, Beacon Angels, TiE Boston Angels, Boston Harbor Angels, and additional investors. Alongside the financing, Crowell also advised on GelMEDIX’s first strategic collaboration with a global pharmaceutical company. Under the terms of the agreement, GelMEDIX will provide its hydrogel scaffold technology, which the partner will use in combination with several of its own cell lines to develop stem cell derived cell therapies.

New York – August 19, 2025: Crowell & Moring represented Halda Therapeutics in a strategic research collaboration, worth over $1 billion in total potential value, with VantAI to discover next-generation RIPTAC (Regulated Induced Proximity Targeting Chimeras) medicines.

In our fifth alert in this EU Pharma Package Series, we provided an analysis of the background and ongoing legal debates regarding the concept of the global marketing authorization (GMA). We discussed in particular the missed opportunities in the Pharma Package to further codify and clarify the GMA, in view of its central role in determining the regulatory data protection (RDP) rights of a medicinal product.

In our fourth alert in this EU Pharma Package Series, we provided an analysis of the long-standing but increasingly debated issue of fiscal imports in the pharmaceutical supply chain and the EU’s evolving approach to this issue.

On April 2, 2026, President Trump issued a Proclamation invoking Section 232 of the Trade Expansion Act of 1962, as amended (19 U.S.C. § 1862), to impose tariffs on imports of patented pharmaceuticals, biologics, and associated ingredients into the United States.  The action affects pharmaceutical manufacturers, importers, and supply chain participants.   

The landscape of AI governance and regulation is shifting. Following the release of the White House’s “America’s AI Action Plan” in July 2025 and the President’s signing of related Executive Orders, the White House has emphasized (at least rhetorically) a preference for innovation, adoption, and deregulation. But that does not tell the entire story. The Administration remains committed to exercising a heavy hand in AI, including by banning the U.S. government’s procurement of so-called “woke AI,” intervening in the development of data centers and the export of the AI technology stack, imposing an export fee for certain semiconductors to China, and assuming a stake in a U.S. semiconductor company. State legislatures are also racing to implement their own regulations, particularly around AI’s use in critical areas, such as healthcare, labor and employment, and data privacy. The many sources of regulation raise the specter of a fragmented compliance environment for businesses. This webinar will delve into the Administration’s AI strategy, going beyond the headlines to analyze:

On October 16, 2025, Partner Matthew F. Ferraro, Partner and CHS Managing Director Jason Johnson, and Counsels Jacob Canter and Anna Z. Saber hosted a webinar on the shifting dimensions of AI governance and regulation. They discussed federal policy, state laws, international efforts, and key court cases and how these many sources of regulation serve to fragment the AI compliance environment for businesses and how firms can respond. Click here to view the webinar on demand.